The importance of the National Guideline Clearinghouse™ (NGC) cannot be validated by someone continuing the work. Its importance was established in 2008 by U.S. Congress. Without appropriate oversight in the development of this content, anything might be called “quality” imperiling the well-being of injured workers. Here is my take on why “WorkComp Needs Quality Measures for Clinical Practice Guidelines”.
Is there a correlation between America’s increased #Suicide rates and the #OpioidEpidemic? The negative effects of inappropriately prescribed #Opioids on public health are multiple. However, the data shows that there is a promising #PatientCentric solution that is highly effective in preventing the inappropriate first exposure to opioids for #Patients.
The national #WorkersCompensation community is at risk of losing the plot of the #OpioidEpidemic. The assault against opioid abuse may be relying too much on over-simplified medicine. It is essential to expand the conversation to emphasize the importance of the overall care of a patient and improve the tracking of health outcomes. The discussion can no longer be just about drugs and potential savings.
I had the humbling opportunity to write a piece for @WorkCompCentral’s #WorkCompWorld blog earlier this week. The theme is #PatientEngagement in #WorkersCompensation. Be sure to read the blog and share your thoughts on why, or why not, the industry is on the right track in this area. Please limit your remarks to #PatientEngagement as it pertains to #WorkComp.
As an aside, I’m ecstatic that the #CompLaudeGala is just a few days away. @ReedGroup is a sponsor of the #InjuredWorkerScholarship this year. I cannot wait to speak with as many #Patients / #Workers as possible. If you’re planning on attending the event, please help point me in the right direction! See you there!
As Louisiana HB 592 moves through legislature, Texas’ workers’ compensation system is again the center of national discussion. Texas Commissioner Ryan Brennan doubled down on advocacy for other states to adopt the Texas-model formulary proclaiming it “a model for the nation” and “the inspiration for many other states’ proposed formularies” citing improvements in return-to-work, medical costs and access to care. Surely, a system as unique as Texas relies on more than a binary list of drugs to accomplish the outcomes documented in its 2016 biennial report. Here is “The Truth Regarding Outcomes in Texas and the Guideline Never Discussed”. Due to reference of the Texas Labor Code, I welcome feedback specifically from the legal community on this piece.
The debate in Louisiana on a drug formulary continues. While HB 592 is being sent to House floor for a vote early next week, HB 529 remains in waiting. Here are my thoughts on why the Texas-model may not produce the expected results in Louisiana.